Cipla Targets FY2026 Growth with Launch of Gadvair, Peptide Therapies, and Respiratory Assets

Cipla has outlined an ambitious product pipeline for calendar year 2026, signaling strong momentum in its U.S. and global operations. According to Managing Director & Global CEO Umang Vohra, the company expects to launch Gadvair—a generic version of Advair—alongside three peptide assets, including liraglutide, a GLP-1 receptor agonist used in diabetes and obesity treatment. These launches are part of Cipla’s broader strategy to tap into the growing demand for GLP-1 therapies and complex generics.

In addition, Cipla plans to roll out four major respiratory products, reinforcing its leadership in pulmonary care. The company is also targeting EBITDA margins of 23.5–24.5% for FY2026, supported by strong performance in North America and sustained growth in India. Despite headwinds from the loss of exclusivity on generic Revlimid, Cipla remains confident in outperforming the industry’s 8–10% growth rate.

Key highlights and major takeaways

• Launches by CY 2026: Gadvair, 3 peptide assets (including liraglutide), 4 respiratory products  
• Therapeutic focus: GLP-1, diabetes, obesity, respiratory care  
• Target markets: U.S., India, global generics  
• Financial outlook: EBITDA margins of 23.5–24.5%  
• Strategic goal: Offset Revlimid impact, drive innovation-led growth  

Sources: Moneycontrol, Med Path, Cipla Investor Presentation